Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9(1):2024.

Hopkins BD, Pauli C, Du X, Wang DG, Li X, Wu D, et al. Publisher Correction: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;563(7731):E24.

Goyal A, Zhang G, Yang B. Differential expression patterns of GATA3 in usual and differentiated types of vulvar intraepithelial neoplasia: potential diagnostic implications. Mod Pathol. 2018;31(7):1131-1140.

Chen Y-, Chen Z, Du Y-. Immunohistochemical analysis of RHAMM expression in normal and neoplastic human tissues: a cell cycle protein with distinctive expression in mitotic cells and testicular germ cells. Oncotarget. 2018;9(30):20941-20952.

Mechery V, Hernandez T, Mathew AT, Wanchoo R, Seshan SV, Jhaveri KD, et al. Nephropathology Education During Nephrology Fellowship Training in the United States. Kidney Int Rep. 2018;3(2):236-241.

Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pertega-Gomes N, et al. MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(2):201-207.

Georgesen C, Magro C. Eruptive Keratoacanthoma-Like Discoid Lupus Erythematosus. Am J Dermatopathol. 2018;40(6):423-427.

Nguyen GH, Mohler A, Leppert M, Parra C, Zeng Y-, Prok L, et al. Index Case of Cutaneous Follicular Mycosis Fungoides With Central Nervous System Involvement and Review of Literature. Am J Dermatopathol. 2018;40(3):185-190.

Nottegar A, Tabbo F, Luchini C, Brunelli M, Bria E, Veronese N, et al. Pulmonary Adenocarcinoma With Enteric Differentiation: Immunohistochemistry and Molecular Morphology. Appl Immunohistochem Mol Morphol. 2018;26(6):383-387.

Gordon JK, Martyanov V, Franks JM, Bernstein EJ, Szymonifka J, Magro C, et al. Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial. Arthritis Rheumatol. 2018;70(2):308-316.